UNSPSC 51283301: Cycloserine

This classification denotes an antitubercular agent with the molecular formula C3H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95IK5KI84Z, chemically known as 3-isoxazolidinone, 4-amino-, (s)- but generally known as cycloserine, which bears US NIH Compound Identifier 401. European Medicines Agency schedules Cycloserine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06863MIG.

UNSPSC 51283301 Cycloserine, a Commodity code, nominally names a specific antibiotic active pharmaceutical ingredient, but recent state and local opportunities show that this code tags a broader pharmaceutical procurement category encompassing generic multi-source pharmaceuticals, over-the-counter products, naloxone, and emergency medical supplies — indicating significant categorical mislabeling or overbroad code assignment in state and local systems. State and local governments are acquiring these products through a mix of issuing bodies: state health agencies and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering contracts across state and local members), county health departments (Seminole County, Florida), city fire and rescue divisions (City of Tampa), and state-level HHS commissions (Texas Health and Human Services Commission). The work ranges from direct pharmaceutical manufacturing contracts with pricing based on National Drug Codes and wholesaler relationships, to naloxone procurement for community health initiatives with quarterly delivery cycles, to emergency medical consumables for first responder use. Recent opportunities show both market-intelligence gathering (Texas HHS RFI on direct-to-manufacturer prescription programs) and formal competitive sealed-bid processes (City of Tampa IFB for medical and first aid supplies with a $700,000 estimated value, open to certified Small Local Business Enterprises with a 5 percent bid discount).

The highest recent activity concentrates in Florida, Minnesota, and Texas. The Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802, due March 26, 2026) seeks manufacturers of generic pharmaceuticals and OTC products for distribution across state and local government facilities, with awards effective July 1, 2026, and pricing weighted 75 percent toward competitiveness. The City of Tampa's IFB 26P00145 (due March 13, 2026) solicited 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with award to the lowest responsive, responsible bidder and a one-year initial term plus two optional one-year renewals. Seminole County, Florida's IFB 60459723LAS (due July 26, 2023) procured 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries. The Texas Health and Human Services Commission's RFI (HHS0017013, response due April 3, 2026) gathered vendor capability information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. All procurements require vendor compliance with federal regulatory frameworks, insurance coverage minimums, and in the City of Tampa's case, SLBE participation and payment-tracking reporting under local ordinance.